the aid library

LIST OPTIONS

Filter

3970

Role of Information Sources in Vaccination Uptake: Insights From a Cross-Sectional Household Survey in Sierra Leone, 2019

Kulkarni, S.; et al. (2022) C1

Global Health Science and Practice February 2022, https://doi.org/10.9745/GHSP-D-21-00237 Key Findings: Exposure to vaccination information from faith leaders and health facilities was associated with increased likelihood of vaccination uptake. The significant association between exposure to a... more

Download (430)

View PDF (555)

Indonesia: National AIDS Commission 2007-2010 HIV and AIDS Response Strategies

National AIDS Commission Indonesia (2007) C1

Download (595)

View PDF (301)

Pakistan Humanitarian Response Plan 2021 (April 2021)

Office for the Coordination of Humanitarian Affairs OCHA (2021) C2

Download (358)

View PDF (288)

Pocketbook for management of Diabetes in Childhood and Adolescence in under-resourced Countries

Ogle, G.; Middlehurst, A.; Silink, M.; Hanas, R. International Diabetes Federation (2017) CC2

The document "Pocketbook for Management of Diabetes in Childhood and Adolescence in Under-Resourced Countries" (2nd Edition) provides practical guidelines for managing diabetes in children and adolescents, particularly in resource-limited settings. It covers key topics like diagnosing and treating d... more

Download (1272)

View PDF (1468)

Best practice guidelines for mental health promotion programs: Refugees

Centre for Addiction and Mental Health (CAMH); Dalla Lana School of Public Health, University of Toronto; Toronto Public Health (2012) C1

This resource is the third in a series of online guides for promoting positive mental health across the lifespan. This resource provides health and social service providers (“practitioners”) with current evidence-based approaches in the application of mental health promotion concepts and princip... more

Download (422)

View PDF (396)

Special edition: HIV in MSM

I. Steffens; K. Hagmaier; K. Wilson; et al. Eurosurveillance (Europe’s journal on infectious disease epidemiology, prevention and control); European Centre for Disease Prevention and Control (2015) C2

Eurosurveillance Impact Factor 5.7 June 2015 www.eurosurveillance.org Featuring a series of articles on HIV and STI epidemiology, prevention and control among MSM in Europe

Download (582)

View PDF (622)

App for its Medical Eligibility Criteria for Contraceptive Use

Johns Hopkins Bloomberg School of Public HealthCenter for Communication Programs and World Health Organization (2022) C_WHO

Recommendations on the initiation and continuing use of nine common types of contraceptive methods are covered by the tool. In addition to looking at individual medical conditions or characteristics, users may also easily combine multiple conditions or characteristics and view the guidance on each c... more

Download (1194)

View PDF (996)

Nepal: Statistics & Information of MDR and XDR TB in SAARC Region

SAARC TB and HIVAIDS Centre (STAC) (2016) C1

Download (359)

View PDF (423)

Practice Education in Nursing

Registered Nurses’ Association of Ontario (RNAO) (2016) CC

The purpose of this Guideline is to provide evidence-based recommendations that promote and sustain the undergraduate nursing student’s application of knowledge to practice in a variety of clinical learning environments. The Guideline explores the relationships among and between students and nursi... more

Download (437)

View PDF (396)

The Global strategy and action plan on ageing and health

World Health Organization WHO (2017) C_WHO

Specifically the Strategy focuses on five strategic objectives: commitment to action on Healthy Ageing in every country; developing age-friendly environments; aligning health systems to the needs of older populations; developing sustainable and equitable systems for providing lon... more

Download (619)

View PDF (621)

Comprehensive Evaluation of the Community Health Program in Rwanda (FINAL REPORT)

Centre for Maternal and Newborn Health (CMNH), from the Liverpool School of Tropical Medicine (LSTM) (2016) C2

The objective of the evaluation is to understand whether the CHW program has achieved its intended objectives, thus contributing to the overarching objectives defined in the HSSP III of improving the health status of the population by “Ensuring universal accessibility of quality health services fo... more

Download (266)

View PDF (520)

The Global Burden of Disease Study at 30 years

Murray, C.J.L. nature medicine (2022) CC

The Global Burden of Disease Study (GBD) began 30 years ago with the goal of providing timely, valid and relevant assessments of critical health outcomes. Over this period, the GBD has become progressively more granular. The latest iteration provides assessments of thousands of outcomes for diseases... more

Download (724)

View PDF (736)

Contextual Factors Influencing Modern Contraceptive Use in Nigeria

Ejembi, Clara Ladi, Tukur Dahiru, and Alhaji A. Aliyu ICF International (2015) C2

DHS Working Papers No. 120

Download (332)

View PDF (757)

The reality of managing asthma in sub-Saharan Africa – Priorities and strategies for improving care

Mortimer, K.; Masekela, R.; Ozoh, O.; et al. (2022) CC2

Asthma is the most common non-communicable disease in children and remains one of the most common throughout the life course. The great majority of the burden of this disease is seen in low-income and middle-income countries (LMICs), which have disproportionately high asthma-related mortality relati... more

Download (483)

View PDF (532)

Global vaccine safety blueprint 2.0 (GVSB2.0) 2021-2023

World Health Organization WHO (2022) C_WHO

Download (597)

View PDF (788)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (518)

View PDF (1164)

Communicable disease surveillance and response systems

World Health Organization WHO (2006) C_WHO

Guide to monitoring and evaluating

Download (470)

View PDF (393)

Quick guide to video-supported treatment of tuberculosis (2020)

World Health Organization WHO, Regional Office of Europe (2020) C_WHO

Despite being a curable and preventable disease, tuberculosis (TB) remains as one of the major challenges for health systems, globally. Every year, TB affects more than 10 million people and kills more than 1.4 million people. WHO’s Digital Health for the End TB Strategy – an Agenda for Action o... more